Epidemiologic and clinical features of anaphylaxis in Korea

Yang, Min‐Suk; Lee, So Hee; Kim, Tae‐Wan; Kwon, Jae-Woo; Lee, Sang‐Min; Kim, Sae‐Hoon; Kwon, Hyouk-Soo; Park, Changhan; Park, Heung-Woo; Kim, Sun-Sin; Cho, Sang Heon; Min, Kyung-Up; Kim, You-Young; Chang, Yoon‐Seok

doi:10.1016/s1081-1206(10)60401-2

Cited by 124 publications

(109 citation statements)

References 19 publications

Supporting

Mentioning

103

Contrasting

Order By: Relevance

“…By contrast, few reports [10,11,12] have analyzed the incidence of anaphylaxis during admission to hospital. Most studies analyze patients who have been admitted after attending the emergency room due to an episode of anaphylaxis [13,14,15,16,17,18,19,20,21,22]. …”

Section: Introductionmentioning

confidence: 99%

Incidence of Anaphylaxis in Hospitalized Patients

Tejedor-Alonso

Moro²,

Hernández³

et al. 2011

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: Only two studies have analyzed the incidence of anaphylaxis during admission to hospital. We have analyzed the incidence of anaphylaxis among hospitalized patients and determined the timing of and risk factors for episodes of anaphylaxis. Methods: Our study was performed between 1999 and 2005. We used the definition of anaphylaxis of the NIAID-FAAN symposium. Cases of anaphylaxis were extracted from an official database of discharge diagnoses coded according to the International Classification of Diseases, Clinical Modification, Ninth Revision (ICD-9-CM), Sixth Edition. Specific and generic codes related to anaphylaxis were chosen. This strategy revealed 83.3% (95% confidence interval, CI, 47–99%) of all episodes of anaphylaxis in a pilot study. The incidence of episodes of anaphylaxis and the hazard ratios were calculated for the different variables. Results: We observed a crude cumulative incidence of 1.5 episodes of anaphylaxis (95% CI, 0.9–1.9) in 5,000 admissions. The cumulative incidence according to the Standardized European Population was 1.6 cases in 5,000 admissions (95% CI, 0.8–2.3). Cox regression analysis showed that anaphylaxis occurs mainly in young people (0.97; 95% CI, 0.95–0.99) and its incidence differs according to the clinical unit. The Vascular Surgery Unit had the highest incidence rate (hazard ratio 7.7; 95% CI, 2.1–28.6). Males had a lower risk of suffering from anaphylaxis than females (0.5; 95% CI, 0.2–0.9). Conclusions: Anaphylaxis is a very rare event among hospitalized patients. Female gender, young age and admission to the Vascular Surgery Unit favored the occurrence of episodes of anaphylaxis among hospitalized patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Incidence of Anaphylaxis in Hospitalized Patients

Tejedor-Alonso

Moro²,

Hernández³

et al. 2011

Int Arch Allergy Immunol

View full text Add to dashboard Cite

show abstract

“…Despite a low prevalence of buckwheat allergy, it is one of the major foods causing severe life‐threatening reactions 3, 4, 5, 6, 7, 9. As neither skin testing nor the presence of buckwheat‐sIgE proved to be useful for precisely predicting clinical allergy, the diagnosis is still based on a positive food challenge and/or a clear‐cut history of severe reactions.…”

Section: Discussionmentioning

confidence: 99%

“…This is an important issue because buckwheat is often consumed as a hidden allergen in cakes, pancakes, and pastries. In Japan, it is estimated that 2.9%‐3.4% of all reported anaphylactic events to foods are caused by buckwheat,6 while in Korea, buckwheat has been identified as the leading cause of food allergy 7. In Europe, data concerning the prevalence of buckwheat allergy are limited to date.…”

Section: Introductionmentioning

confidence: 99%

Concomitant sensitization to legumin, Fag e 2 and Fag e 5 predicts buckwheat allergy

Geiselhart

Nagl

Dubiela

et al. 2017

Clin Experimental Allergy

View full text Add to dashboard Cite

SummaryBackgroundBuckwheat (Fagopyrum esculentum) has become increasingly popular as a healthy food in Europe. However, for sensitized individuals, consumption can cause anaphylactic reactions. The aim of this study was to identify individual well‐characterized buckwheat allergens for component‐resolved diagnosis.MethodsPatients were selected by positive skin prick test to buckwheat and divided into two groups: (1) sensitized to buckwheat without clinical symptoms and (2) buckwheat allergy. Buckwheat proteins were extracted from raw buckwheat seeds, purified applying a combination of protein precipitation and chromatographic methods, and analyzed by IgE immunoblotting and ELISA.ResultsBuckwheat‐allergic patients had a significantly larger median skin prick test weal diameter for buckwheat than the sensitized group and the positive control. Also, IgE immunoblotting clearly showed a distinct pattern in sera from allergic patients when compared to sensitized individuals. Several IgE‐reactive proteins were purified from crude buckwheat extract, namely legumin (Fag e 1 plus its large subunit), Fag e 2 (2S albumin), and newly identified Fag e 5 (vicilin‐like) as well as hevein‐like antimicrobial peptides, designated Fag e 4. All four allergens showed superior diagnostic precision compared to extract‐based ImmunoCAP with high sensitivity as well as high specificity.ConclusionsPatients with clinical symptoms clearly show a distinct allergen recognition pattern. We characterized a buckwheat vicilin‐like protein as a new relevant marker allergen, designated Fag e 5. Additionally, another new allergen, Fag e 4, potentially important for cross‐reactivity to latex was added to the allergen panel of buckwheat. Further, our data show that the full‐length legumin comprising both, large and small subunit should be applied for component‐resolved diagnosis. Our data indicate that concomitant sensitization to legumin, Fag e 2 and Fag e 5, predicts buckwheat allergy.

show abstract

“…However, many of the allergic reactions were elicited by buckwheat as hidden allergen in dishes that were not supposed to contain it (therefore acting as "hidden allergen"), and also these unexpected allergic reactions occurred more frequently in Northern Italian regions. The prevalence of buckwheat anaphylaxis seems to be of certain relevance in Asia (3.4% of all food anaphylaxis according to a Japanese survey on patients with food allergy [13] and 2.9% according to a Korean retrospective study on patients reporting anaphylaxis [14]), while it is still unknown the prevalence of buckwheat anaphylaxis in Europe. A French study which analysed all the food anaphylaxis cases reported to the "French Allergy Vigilance Network", showed that about 4.5% of them were due to buckwheat allergy [15], while an Italian epidemiological survey on food anaphylaxis reported a prevalence of about 1% of buckwheat anaphylaxis [16].…”

Section: Epidemiology Of Buckwheat Sensitization and Allergymentioning

confidence: 99%

Buckwheat Allergy: An Emerging Clinical Problem in Europe

Heffler¹,

Pizzimenti²,

Badiu³

et al. 2014

J Allergy Ther

View full text Add to dashboard Cite

Buckwheat allergy is a clinical entity known since long time ago and frequent in Asia, where this crop is commonly eaten. In Europe, buckwheat allergy was an anedoctical description since few years ago, when the consumption of buckwheat dramatically increased together with the publication of case reports and case series of European patients with buckwheat allergy.This review article describes and analyzes the history of buckwheat allergy, its clinical presentation, its increase in European countries during the last few years, and summarizes the main case reports, case series and epidemiological surveys on buckwheat allergy.A summary of main buckwheat allergens and clinical relevant cross-reactivity are also described and discussed.

show abstract

Epidemiologic and clinical features of anaphylaxis in Korea

Cited by 124 publications

References 19 publications

Incidence of Anaphylaxis in Hospitalized Patients

Incidence of Anaphylaxis in Hospitalized Patients

Concomitant sensitization to legumin, Fag e 2 and Fag e 5 predicts buckwheat allergy

Buckwheat Allergy: An Emerging Clinical Problem in Europe

Contact Info

Product

Resources

About